Firefly Neuroscience, INC

Firefly Neuroscience, Inc. announced that its stockholders approved significant amendments to its charter and long-term incentive plan at the 2026 annual meeting.

Firefly Neuroscience, Inc. announced a Securities Purchase Agreement for up to $1 million in gross proceeds through the sale of units, each comprising common stock and two types of warrants.

Firefly Neuroscience has completed an additional $8 million private placement, issuing 5.33 million units at $1.50 per unit.

Firefly Neuroscience, Inc. announced an initial $2.25 million private placement with accredited investors, including warrants and potential for an additional $18 million.

Firefly Neuroscience, Inc. announced an At-the-Market offering for up to $7.4 million and revised its CTO's compensation structure, replacing an automatic bonus with a discretionary one.

Firefly Neuroscience, Inc. exchanged existing warrants with higher exercise prices for new warrants at a significantly reduced exercise price of $0.50 per share, aiming to raise up to $400,000.

Firefly Neuroscience reported a significant revenue increase in Q3 2025 driven by the Evoke acquisition, yet net losses expanded due to derivative fair value changes and an intangible asset impairment.

Firefly Neuroscience, Inc. reported a significant net loss for Q2 2025, driven by increased operating expenses and non-cash charges, despite a substantial revenue increase primarily due to the Evoke Neuroscience acquisition.

Firefly Neuroscience's Q1 2025 shows revenue growth alongside a significant increase in net loss, highlighting ongoing concerns about the company's financial stability and internal controls.

Firefly Neuroscience, formerly WaveDancer, reports its Q3 2024 results, reflecting a reverse merger and ongoing development of its Brain Network Analytics platform.

Firefly Neuroscience, formerly WaveDancer, reported its second quarter 2024 results, highlighting a strategic shift towards commercializing its Brain Network Analytics (BNA) platform after a recent merger.

WaveDancer Inc. reported a net loss of $673,950 for the first quarter of 2024, while navigating a planned merger and ongoing financial constraints.

Firefly Neuroscience, Inc. reported a 957% revenue increase to $1.142 million in 2025, driven by the Evoke acquisition, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Firefly Neuroscience's latest 10-K filing highlights its focus on AI-driven neuroscientific solutions and commercial launch of the BNA Platform, while also acknowledging substantial doubt about its ability to continue as a going concern.

WaveDancer Inc. reports a net loss for 2023, while undergoing a strategic shift including the sale of a subsidiary and a planned merger.

Firefly Neuroscience's President and COO, David DeCaprio, vested 44,872 shares of common stock after performance conditions were met for previously granted restricted stock units.

Gregory Lipschitz, CEO and Director of FIREFLY NEUROSCIENCE, INC., increased his beneficial ownership by 65,988 shares through RSU vesting.

Firefly Neuroscience director Arun Menawat received a grant of 73,892 deferred stock units, vesting quarterly over 12 months.

Firefly Neuroscience, Inc. Director Brian M. Posner was granted 49,262 deferred stock units under the company's 2024 Long-Term Incentive Plan.

Stella Vnook, a Director at Firefly Neuroscience, Inc., was granted 49,262 deferred stock units under the company's 2024 Long-Term Incentive Plan.

Windsor Private Capital LP and its affiliated entities have sold a significant portion of their common stock in Firefly Neuroscience, Inc., ceasing to be a 10% beneficial owner.

Firefly Neuroscience, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for August 5, 2026, to address key corporate matters including director elections, auditor ratification, executive compensation, and amendments to incentive plans and the company's charter.

Firefly Neuroscience, Inc. filed an amendment to its definitive proxy statement, revising Proposal 4 to seek approval for a fixed increase in authorized shares from 101 million to 5.001 billion.

Firefly Neuroscience, Inc. will hold its Annual Meeting on October 27, 2025, seeking stockholder approval for director elections, auditor ratification, and significant increases in its equity incentive plan and total authorized shares.

Firefly Neuroscience is requesting shareholder approval to issue more than 20% of its common stock to two entities, Helena Special Opportunities LLC and Arena Business Solutions Global SPC II, Ltd, to comply with Nasdaq listing rules and secure necessary financing.

Firefly Neuroscience will hold its 2024 annual meeting of stockholders virtually on December 27, 2024, to vote on the election of directors, ratification of auditors, and executive compensation matters.

Firefly Neuroscience, an AI-driven neuroscientific solutions company, has filed an S-1 registration statement for the resale of over 6 million common shares, while reporting substantial accumulated deficits and negative cash flows that raise significant doubt about its ability to continue as a going concern.

Firefly Neuroscience is registering for resale up to 4.5 million shares of its common stock, including shares issuable upon conversion of a convertible note, exercise of warrants, and potential sales under an equity line of credit agreement.

Firefly Neuroscience, Inc. files an amendment to its registration statement, detailing the offering of over 2.5 million shares of common stock and underlying warrants.

Firefly Neuroscience is registering for resale 2,559,645 shares of common stock by selling securityholders, including shares from private placements, warrant exercises, and conversions.

Firefly Neuroscience, Inc. has filed an amended S-1 registration statement detailing the resale of common stock and warrants following its reverse merger with WaveDancer, Inc.

Firefly Neuroscience registers for the resale of up to 2.56 million shares of common stock by selling securityholders following its recent reverse merger with WaveDancer.

A group of reporting persons, including Windsor Private Capital LP and Jordan Kupinsky, have reduced their beneficial ownership in Firefly Neuroscience, Inc. below the 5% threshold, triggering an exit filing.

Windsor Private Capital and affiliated entities have significantly reduced their beneficial ownership in Firefly Neuroscience, Inc. by selling 185,800 common shares.

Windsor Private Capital and its affiliates have reduced their beneficial ownership in Firefly Neuroscience, Inc. to 7.0% through recent share sales.

Key reporting persons, including Windsor Private Capital LP and Jordan Kupinsky, have reduced their beneficial ownership in Firefly Neuroscience, Inc. by selling 134,000 common shares.

Key reporting persons, including Windsor Private Capital LP and Jordan Kupinsky, have reduced their beneficial ownership in Firefly Neuroscience, Inc. through recent open market sales.

A group of insiders, including Windsor Private Capital LP and Jordan Kupinsky, reduced their beneficial ownership in Firefly Neuroscience, Inc. through open market sales and dilution from increased outstanding shares.

Arena Investors and its affiliates have reported zero beneficial ownership in Firefly Neuroscience, Inc. common stock as of March 31, 2025.

Roxy Capital Corp has filed an amended Schedule 13G, disclosing a 3.65% beneficial ownership stake in Firefly Neuroscience, Inc.'s common stock.

Arena Investors and its affiliates have disclosed a 9.0% beneficial ownership stake in Firefly Neuroscience, Inc., acquiring 800,000 shares through the conversion of a convertible promissory note.

Christopher Finn, Eadwacer Holdings, LLC, and Harleston Capital LLC have jointly filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 4.1% in Firefly Neuroscience, Inc.'s common stock as of December 31, 2024.